Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 689 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Prostate cancer: Lessons Learned from My Breast Cancer June 23, 2021 A Novel Model Helps Better Predict Risk of Cancer Development in... April 15, 2024 Load more HOT NEWS A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... Giving Myself the Most Time and Best Chance at Beating Cancer:... Returning to Dental Care Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC...
